ClinicalTrials.gg
RecruitingNCT07674277RELIEVE-SCDUpdated Oct 16, 2026

Virtual Reality for SCD VOC

An interventional study of Sham 2D Headset Control and Passive Immersive 3D Virtual Reality in Sickle Cell Disease, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 88 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Planned enrollment
194th of 559
50 · median 31
Started
2026
with 28 others
No phase
165 of 733
36 open now
Primary completion
2027-12
later than 101 of 182 live
Registered
725th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 194th largest by planned enrollment of the 559 interventional ones that give a count, is one of 29 that started in 2026, is one of 165 with no phase, reaches primary completion later than 101 of the 182 other live ones, and was the 725th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

128 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 88 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This randomized pilot study will evaluate the feasibility, tolerability, and preliminary analgesic effect of headset-based virtual reality (VR) interventions for adults with sickle cell disease (SCD) experiencing vaso-occlusive crisis (VOC) treated in an infusion center. Up to 50 participants will be enrolled, provide informed consent, and undergo randomization during routine outpatient sickle cell clinic visits when they are clinically stable and not experiencing an acute VOC.

Using a randomized, two-period crossover design, each participant will be assigned to receive two of three headset-based interventions during separate qualifying infusion center visits for vaso-occlusive pain occurring within six months of enrollment: sham 2D headset control, passive immersive 3D VR, or active immersive interactive 3D VR. Each intervention will be delivered during a 45-minute session as an adjunct to usual clinical care.

The primary outcome is pain burden during the first 60 minutes after intervention start, measured as the area under the curve of 0-10 numeric rating scale pain scores. Secondary outcomes include feasibility of intervention delivery, headset tolerability, pain at 120 minutes, opioid consumption, and participant-reported immersion and acceptability. Findings will inform the design of future trials evaluating VR as an adjunctive treatment for acute vaso-occlusive pain.

Read the detailed description

Vaso-occlusive crisis (VOC) is a common and debilitating complication of sickle cell disease (SCD) and is a frequent reason for treatment in acute care settings, including infusion centers and emergency departments. Opioid analgesics remain the mainstay of treatment for acute vaso-occlusive pain, but many patients continue to experience substantial pain, distress, and functional impairment despite standard therapy. Scalable, low-risk, non-pharmacologic adjuncts are needed to improve pain management during acute vaso-occlusive episodes.

Virtual reality (VR) is a promising non-pharmacologic approach to pain management that may reduce pain through immersive distraction, modulation of attention, and enhanced patient engagement. Prior studies suggest that VR may reduce acute and chronic pain in some clinical settings, but its effect may vary by population and condition. Limited data are available regarding the use of VR for acute vaso-occlusive pain in adults with SCD. This study is designed to evaluate the feasibility, tolerability, and preliminary analgesic effect of headset-based visual and audio interventions during infusion center treatment of VOC.

This is a randomized, controlled, two-period crossover pilot study using a balanced incomplete block design. Up to 50 participants will be enrolled during routine outpatient sickle cell disease clinic visits when they are clinically stable and not experiencing an acute VOC. Written informed consent and randomization will occur during these outpatient visits and will not occur during an acute VOC infusion center encounter. Following enrollment, participants will be eligible to receive study interventions during qualifying infusion center visits for vaso-occlusive pain occurring within six months of enrollment. At each qualifying visit, study staff will confirm continued eligibility, clinical appropriateness, and the participant's willingness to proceed before delivering the assigned intervention.

Each participant will be randomized to receive two of three headset-based intervention conditions across two separate qualifying infusion center visits. The three conditions are:

  • **Sham 2D headset control:** Non-interactive two-dimensional nature-related video content displayed on a fixed virtual screen with standardized audio.
  • **Passive immersive 3D VR:** Immersive three-dimensional visual content delivered using the Nature Treks application with standardized audio, allowing participants to look around the virtual environment without controller-based interaction.
  • **Active immersive interactive 3D VR:** Immersive interactive content delivered using the Nature Treks application with standardized audio, allowing participants to interact with the virtual environment using controllers while completing low-motion, seated activities.

All three intervention conditions will be delivered using the Meta Quest 2 headset platform. Each intervention session is planned to last 45 minutes and will be provided as an adjunct to usual clinical care for VOC. Participation will not alter clinical management, including opioid administration, rescue analgesia, fluid administration, monitoring, or disposition decisions.

Randomization will assign each participant to one of three possible intervention pairs: sham 2D plus passive immersive 3D VR, sham 2D plus active immersive interactive 3D VR, or passive immersive 3D VR plus active immersive interactive 3D VR. Within each pair, the order of interventions will be randomized to balance period and sequence effects, resulting in six possible intervention sequences. Participants and study staff will not be blinded to the intervention condition because the interventions are perceptible; however, the use of a headset-based control condition and standardized scripts is intended to reduce differences in attention and expectancy across conditions.

The primary outcome is pain burden during the first 60 minutes after intervention start, measured as the area under the curve of 0-10 numeric rating scale pain scores. Pain scores will be collected before intervention and at 15, 30, 45, and 60 minutes after intervention start. Secondary and exploratory outcomes include pain at approximately 120 minutes, change in pain from baseline to 120 minutes, opioid administration summarized as morphine milligram equivalents, need for rescue analgesia, feasibility of intervention delivery, session completion, missing pain assessments, early discontinuation, headset-related adverse symptoms, perceived immersion, and participant-reported likelihood of using the intervention again during future VOC treatment.

The study will enroll a convenience sample of up to 50 participants based on the expected eligible infusion center population. Each participant may complete up to two intervention sessions during separate qualifying infusion center visits within six months of enrollment. The primary purpose of this pilot study is to estimate feasibility, tolerability, preliminary treatment effects, and variability to inform the design of a future larger efficacy trial.

03

Conditions studied

  • Sickle Cell Disease

Keywords

  • virtual reality (VR)
  • Sickle Cell Disease
  • vaso-occlusive crisis
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants will be identified, screened, and consented during routine outpatient sickle cell disease clinic visits when they are clinically stable and not experiencing an acute vaso-occlusive crisis (VOC). Following enrollment, eligibility for each study intervention session will be confirmed during a qualifying VOC visit to the Stoler Infusion Center. Participants must meet the applicable clinical eligibility criteria and be receiving intravenous opioid treatment for acute vaso-occlusive pain at the time of the intervention visit.

**Inclusion Criteria:**

  • Adult patients aged 18 years or older.
  • History of sickle cell disease.
  • Treatment plan by the clinical care team includes intravenous opioids for acute pain.
  • Receiving treatment through the Stoler Infusion Center.

**Exclusion Criteria:**

  • Prior enrollment in this study.
  • Presentation with a chief complaint suggestive of a complicated vaso-occlusive crisis, including concern for acute chest syndrome, splenic sequestration, hepatic sequestration, or pulmonary embolism, as determined by the treating clinician.
  • Not receiving intravenous opioids for the vaso-occlusive crisis.
  • Inability to provide .
  • Medical history of seizures or known intolerance to virtual reality devices.
  • Preexisting visual or hearing impairments that, in the investigator's judgment, preclude use of a head-mounted virtual reality device.
  • Known pregnancy.
  • Incarceration at the time of evaluation.
  • Age greater than 88 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sham 2D, then Passive 3D VR

    Participants randomized to this sequence will receive the sham 2D headset control condition during the first qualifying vaso-occlusive crisis infusion center visit and the passive immersive 3D virtual reality condition during the second qualifying vaso-occlusive crisis infusion center visit. The sham 2D condition consists of non-interactive 2D visual content displayed on a fixed virtual screen with standardized audio. The passive immersive 3D virtual reality condition consists of 360-degree or 3D immersive visual content with standardized audio, allowing participants to look around without controller-based interaction.

    Device: Sham 2D Headset Control · Device: Passive Immersive 3D Virtual Reality

  • Experimental
    Passive 3D VR → Sham 2D

    Participants randomized to this sequence will receive the passive immersive 3D virtual reality condition during the first qualifying vaso-occlusive crisis infusion center visit and the sham 2D headset control condition during the second qualifying vaso-occlusive crisis infusion center visit. The passive immersive 3D virtual reality condition consists of 360-degree or 3D immersive visual content with standardized audio, allowing participants to look around without controller-based interaction. The sham 2D condition consists of non-interactive 2D visual content displayed on a fixed virtual screen with standardized audio.

    Device: Sham 2D Headset Control · Device: Passive Immersive 3D Virtual Reality

  • Experimental
    Sham 2D → Active 3D VR

    Participants randomized to this sequence will receive the sham 2D headset control condition during the first qualifying vaso-occlusive crisis infusion center visit and the active immersive interactive 3D virtual reality condition during the second qualifying vaso-occlusive crisis infusion center visit. The sham 2D condition consists of non-interactive 2D visual content displayed on a fixed virtual screen with standardized audio. The active immersive interactive 3D virtual reality condition consists of immersive interactive virtual reality content with standardized audio, using low-motion, seated modules with controller-based interaction.

    Device: Sham 2D Headset Control · Device: Active Immersive Interactive 3D Virtual Reality

  • Experimental
    Active 3D VR → Sham 2D

    Participants randomized to this sequence will receive the active immersive interactive 3D virtual reality condition during the first qualifying vaso-occlusive crisis infusion center visit and the sham 2D headset control condition during the second qualifying vaso-occlusive crisis infusion center visit. The active immersive interactive 3D virtual reality condition consists of immersive interactive virtual reality content with standardized audio, using low-motion, seated modules with controller-based interaction. The sham 2D condition consists of non-interactive 2D visual content displayed on a fixed virtual screen with standardized audio.

    Device: Sham 2D Headset Control · Device: Active Immersive Interactive 3D Virtual Reality

  • Experimental
    Passive 3D VR → Active 3D VR

    Participants randomized to this sequence will receive the passive immersive 3D virtual reality condition during the first qualifying vaso-occlusive crisis infusion center visit and the active immersive interactive 3D virtual reality condition during the second qualifying vaso-occlusive crisis infusion center visit. The passive immersive 3D virtual reality condition consists of 360-degree or 3D immersive visual content with standardized audio, allowing participants to look around without controller-based interaction. The active immersive interactive 3D virtual reality condition consists of immersive interactive virtual reality content with standardized audio, using low-motion, seated modules with controller-based interaction.

    Device: Passive Immersive 3D Virtual Reality · Device: Active Immersive Interactive 3D Virtual Reality

  • Experimental
    Active 3D VR → Passive 3D VR

    Participants randomized to this sequence will receive the active immersive interactive 3D virtual reality condition during the first qualifying vaso-occlusive crisis infusion center visit and the passive immersive 3D virtual reality condition during the second qualifying vaso-occlusive crisis infusion center visit. The active immersive interactive 3D virtual reality condition consists of immersive interactive virtual reality content with standardized audio, using low-motion, seated modules with controller-based interaction. The passive immersive 3D virtual reality condition consists of 360-degree or 3D immersive visual content with standardized audio, allowing participants to look around without controller-based interaction.

    Device: Passive Immersive 3D Virtual Reality · Device: Active Immersive Interactive 3D Virtual Reality

Interventions

  • DeviceSham 2D Headset Control

    The sham 2D headset control condition consists of non-interactive, two-dimensional nature-related video content displayed on a fixed virtual screen using the Meta Quest 2 headset platform. The content will be presented through the YouTube application and will depict natural environments similar to those used in the immersive VR conditions. Standardized audio will accompany the visual content. Participants will wear the headset for a planned 45-minute session during a qualifying vaso-occlusive crisis infusion center visit. This condition serves as a headset-based control to maintain similar device exposure and attention across intervention conditions while minimizing immersion and interactivity.

  • DevicePassive Immersive 3D Virtual Reality

    The passive immersive 3D virtual reality condition consists of immersive three-dimensional visual content delivered through the Nature Treks application using the Meta Quest 2 headset platform. Participants will experience immersive natural environments with standardized audio and may look around the virtual environment but will not interact with the content using controllers. Participants will wear the headset for a planned 45-minute session during a qualifying vaso-occlusive crisis infusion center visit. The intervention will be provided as an adjunct to usual clinical care.

  • DeviceActive Immersive Interactive 3D Virtual Reality

    The active immersive interactive 3D virtual reality condition consists of immersive, interactive three-dimensional content delivered through the Nature Treks application using the Meta Quest 2 headset platform. Participants will experience immersive natural environments with standardized audio and interact with the virtual environment using handheld controllers while completing low-motion, seated activities. Participants will wear the headset for a planned 45-minute session during a qualifying vaso-occlusive crisis infusion center visit. The intervention will be provided as an adjunct to usual clinical care.

06

What researchers measure

Primary outcomes

  1. Pain burden during the first 60 minutes after intervention start

    Pain burden will be measured as the area under the curve from 0 to 60 minutes of participant-reported pain scores using an 11-point Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst possible pain. Pain scores will be collected at baseline before intervention start and at 15, 30, 45, and 60 minutes after intervention start. Area under the curve will be calculated using the trapezoidal rule with actual recorded assessment times.

    Time frame: 60 minutes ± 10 minutes

Secondary outcomes

  1. Pain at 120 minutes after intervention start (Durability of effect)

    Pain durability will be assessed using participant-reported pain scores at 120 minutes after intervention start and change in pain score from baseline to 120 minutes. Pain will be measured using an 11-point Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst possible pain. The 120-minute pain assessment will be considered valid if obtained within the prespecified window of 100 to 140 minutes after intervention start. If the participant leaves the infusion center before this window, study staff will attempt to obtain an end-of-encounter pain score with the time recorded.

    Time frame: 120 minutes

  2. Participant-Reported Immersion Rating Immediately After Headset Session

    Perceived immersion will be assessed immediately after headset session completion or early discontinuation using a single participant-reported 0 to 10 rating scale in response to the question, "How immersive did the experience feel?" A score of 0 indicates not immersive at all, and a score of 10 indicates extremely immersive. Higher scores indicate greater perceived immersion.

    Time frame: Immediately after headset session completion or early discontinuation

  3. Participant-Reported Likelihood of Future Use Rating Immediately After Headset Session

    Acceptability will be assessed immediately after headset session completion or early discontinuation using a single participant-reported 0 to 10 rating scale in response to the question, "If available during future vaso-occlusive crisis treatment, how likely would you be to use this again?" A score of 0 indicates not at all likely, and a score of 10 indicates extremely likely. Higher scores indicate greater likelihood of future use.

    Time frame: Immediately after headset session completion or early discontinuation

  4. Opioid consumption during the first 60 minutes after intervention start

    Opioid analgesic administration will be recorded from the medical record and summarized as morphine milligram equivalents during the first 60 minutes after intervention start.

    Time frame: 0 to 60 minutes after intervention start

  5. Opioid consumption during the first 120 minutes after intervention start

    Opioid analgesic administration will be recorded from the medical record and summarized as morphine milligram equivalents during the first 120 minutes after intervention start.

    Time frame: 0 to 120 minutes after intervention start

  6. Headset session completion

    The proportion of initiated headset sessions completed without early discontinuation will be assessed for each intervention condition. Early discontinuation and the reason for discontinuation, including adverse symptoms, clinical interruption, or participant request, will be recorded.

    Time frame: During the 45-minute headset session

  7. Number of Headset Sessions With Any Headset-Related Adverse Symptom

    The number of initiated headset sessions in which the participant reports any headset-related adverse symptom will be recorded for each intervention condition. Headset-related adverse symptoms include nausea, dizziness, headache, eye strain, anxiety, panic, psychological distress, or other symptoms attributed to headset use. This outcome will be reported as a single count of sessions with one or more headset-related adverse symptoms.

    Time frame: From intervention start through immediately after headset session completion or early discontinuation, up to 45 minutes after intervention start

  8. Completion of both assigned intervention periods

    The proportion of enrolled participants who complete both assigned headset intervention periods within the study follow-up window will be assessed.

    Time frame: From enrollment through 6 months after enrollment

07

Study locations

1 of 1 sites recruiting
  • University of Maryland Medical Center, Stoler Infusion Center
    Baltimore, Maryland 21230, United States
    Recruiting
08

References and documents

Publications

  • Mercado SH. An outpatient pain plan and ED pain pathway for adults with sickle cell disease. JAAPA. 2023 Mar 1;36(3):20-23. doi: 10.1097/01.JAA.0000920956.33631.26. PubMed 36752670 ↗
  • Agrawal AK, Robertson S, Litwin L, Tringale E, Treadwell M, Hoppe C, Marsh A. Virtual reality as complementary pain therapy in hospitalized patients with sickle cell disease. Pediatr Blood Cancer. 2019 Feb;66(2):e27525. doi: 10.1002/pbc.27525. Epub 2018 Oct 26. PubMed 30362236 ↗
  • Smith V, Warty RR, Sursas JA, Payne O, Nair A, Krishnan S, da Silva Costa F, Wallace EM, Vollenhoven B. The Effectiveness of Virtual Reality in Managing Acute Pain and Anxiety for Medical Inpatients: Systematic Review. J Med Internet Res. 2020 Nov 2;22(11):e17980. doi: 10.2196/17980. PubMed 33136055 ↗
  • Chuan A, Zhou JJ, Hou RM, Stevens CJ, Bogdanovych A. Virtual reality for acute and chronic pain management in adult patients: a narrative review. Anaesthesia. 2021 May;76(5):695-704. doi: 10.1111/anae.15202. Epub 2020 Jul 27. PubMed 32720308 ↗
  • Williams H, Tanabe P. Sickle Cell Disease: A Review of Nonpharmacological Approaches for Pain. J Pain Symptom Manage. 2016 Feb;51(2):163-77. doi: 10.1016/j.jpainsymman.2015.10.017. Epub 2015 Nov 17. PubMed 26596876 ↗
  • Osunkwo I, Manwani D, Kanter J. Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Ther Adv Hematol. 2020 Sep 29;11:2040620720955000. doi: 10.1177/2040620720955000. eCollection 2020. PubMed 33062233 ↗
  • Duroseau Y, Beenhouwer D, Broder MS, Brown B, Brown T, Gibbs SN, Jackson K, Liang S, Malloy M, Romney ML, Shani D, Simon J, Yermilov I. Developing an emergency department order set to treat acute pain in sickle cell disease. J Am Coll Emerg Physicians Open. 2021 Aug 7;2(4):e12487. doi: 10.1002/emp2.12487. eCollection 2021 Aug. PubMed 34401866 ↗
  • Jang T, Poplawska M, Cimpeanu E, Mo G, Dutta D, Lim SH. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Transl Med. 2021 Sep 20;19(1):397. doi: 10.1186/s12967-021-03074-z. PubMed 34544432 ↗
  • Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol. 2019 Jan 24;14:263-292. doi: 10.1146/annurev-pathmechdis-012418-012838. Epub 2018 Oct 17. PubMed 30332562 ↗

Individual participant data

Plan to share: No — We do not plan on sharing any individual participant data with other researchers

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 165 non-industry interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 13 months is below that.

Counting every sponsor, half of 173 studies reached it within 28 months; a quarter within 15 and three quarters within 49.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Aug 2026 → Nov 2026, primary completion Aug 2027 → Dec 2027 and completion Dec 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2026
First posted
Jun 29, 2026
StartEst.
Nov 1, 2026was Aug 2026
Primary completionEst.
Dec 2027was Aug 2027
CompletionEst.
Mar 2028was Dec 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
University of Maryland Medical Center, Stoler Infusion Center is now Recruiting
Oct 16, 2026
Start date
Aug 1, 2026→Nov 1, 2026
Oct 16, 2026
Primary completion
Aug 2027→Dec 2027
Oct 16, 2026
Study completion
Dec 2027→Mar 2028
Oct 16, 2026
Enrollment
25→50
Oct 16, 2026
Eligibility
Maximum age 89 Years→88 Years; 1 inclusion criterion removed; 2 exclusion criteria removed; 7 criteria edited, 6 added
What changed in the criteria
  • AddedParticipants will be identified, screened, and consented during routine outpatient sickle cell disease clinic visits when they are clinically stable and not experiencing an acute vaso-occlusive crisis (VOC). Following enrollment, eligibility for each study intervention session will be confirmed during a qualifying VOC visit to the Stoler Infusion Center. Participants must meet the applicable clinical eligibility criteria and be receiving intravenous opioid treatment for acute vaso-occlusive pain at the time of the intervention visit.
  • Added**Inclusion Criteria:**
  • AddedAdult patients aged 18 years or older.
  • EditedTreatment plan by the clinical care team includes the use of intravenous opioids to -treatfor acute pain.
  • EditedReceiving treatment fromthrough the Stoler Infusion centerCenter.
  • Added**Exclusion Criteria:**
  • EditedPresentingPresentation with a chief complaint suggestive of a complicated vaso-occlusive crisis (such as, including concern for acute chest syndrome, splenic sequestration, hepatic sequestration, or pulmonary embolism), as determined by the clinical care providertreating clinician.
  • EditedNot being treated withreceiving intravenous opioids for the vaso-occlusive crisis.
  • EditedPatients who lack the capacityInability to provide informed consent.
  • AddedPreexisting visual or hearing impairments that, in the investigator's judgment, preclude use of a head-mounted virtual reality device.
  • AddedKnown pregnancy.
  • EditedIncarceratedIncarceration at the time of evaluation.
  • ChangedBefore Over the age of 89 years oldNow Age greater than 88 years.
Inclusion criteria
  • RemovedAdult (age ≥ 18 years) patients
Exclusion criteria
  • RemovedIn the opinion of the investigator and based on chart review and direct questioning of the patient, there are preexisting disabilities like vision and hearing defects that preclude the use of a head mounted virtual reality device.
  • RemovedKnown to be pregnant
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    University of Maryland Medical Center, Stoler Infusion Center is now Recruiting
    Start date Aug 1, 2026→Nov 1, 2026
    Primary completion Aug 2027→Dec 2027
    Study completion Dec 2027→Mar 2028
    Enrollment 25→50
    Eligibility Maximum age 89 Years→88 Years; 1 inclusion criterion removed; 2 exclusion criteria removed; 7 criteria edited, 6 added
    What changed in the criteria
    • AddedParticipants will be identified, screened, and consented during routine outpatient sickle cell disease clinic visits when they are clinically stable and not experiencing an acute vaso-occlusive crisis (VOC). Following enrollment, eligibility for each study intervention session will be confirmed during a qualifying VOC visit to the Stoler Infusion Center. Participants must meet the applicable clinical eligibility criteria and be receiving intravenous opioid treatment for acute vaso-occlusive pain at the time of the intervention visit.
    • Added**Inclusion Criteria:**
    • AddedAdult patients aged 18 years or older.
    • EditedTreatment plan by the clinical care team includes the use of intravenous opioids to -treatfor acute pain.
    • EditedReceiving treatment fromthrough the Stoler Infusion centerCenter.
    • Added**Exclusion Criteria:**
    • EditedPresentingPresentation with a chief complaint suggestive of a complicated vaso-occlusive crisis (such as, including concern for acute chest syndrome, splenic sequestration, hepatic sequestration, or pulmonary embolism), as determined by the clinical care providertreating clinician.
    • EditedNot being treated withreceiving intravenous opioids for the vaso-occlusive crisis.
    • EditedPatients who lack the capacityInability to provide informed consent.
    • AddedPreexisting visual or hearing impairments that, in the investigator's judgment, preclude use of a head-mounted virtual reality device.
    • AddedKnown pregnancy.
    • EditedIncarceratedIncarceration at the time of evaluation.
    • ChangedBefore Over the age of 89 years oldNow Age greater than 88 years.
    Inclusion criteria
    • RemovedAdult (age ≥ 18 years) patients
    Exclusion criteria
    • RemovedIn the opinion of the investigator and based on chart review and direct questioning of the patient, there are preexisting disabilities like vision and hearing defects that preclude the use of a head mounted virtual reality device.
    • RemovedKnown to be pregnant
    + 4 other changes: verification date, responsible party, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07674277
Responsible party
Richard Gentry Wilkerson (Professor, University of Maryland School of Medicine Department of Emergency Medicine Director of Clinical Research, University of Maryland School of Medicine Department of Emergency Medicine Assistant Residency Program Director, University of Maryland, Baltimore) — Principal investigator
First posted
Jun 29, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Soowon Lee, MSPH
Contact
Soowon.Lee@som.umaryland.edu
254-400-4894
Rose Corcoran
Contact
rose.corcoran@som.umaryland.edu
2407439858
Richard G Wilkerson, MD
principal investigator · Unversity of Maryland School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion